Vaccine against cervical cancer now available in Shanghai

时间:2017-11-10 单词数:3630

双语 中文 英文




A 23-year-old woman has become the first citizen to be inoculated with a vaccine against cervical cancer in a non-private facility in Shanghai.


On Wednesday morning Wu Xinye received an HPV (human papillomavirus) vaccination in the community clinic of Wanggang, one of the first 17 service providers in the Pudong New Area and downtown.


Wu said she learned about the service a couple of weeks ago at the official WeChat account of Pudong Disease Control and Prevention Center. She made an appointment in the community clinic near her workplace.


“I feel good,” she said. “We have access to the world-class health service here in Shanghai.”


On Thursday and Friday, the service will be extended to other 40 grassroots clinics and hospitals in Pudong, including Shanghai International Medical Center and Huashan Hospital Pudong. There will be a total of 4,200 doses of vaccines in stock.


The vaccine is set to be available in other districts by the end of this year. Anyone interested should make an appointment, by contacting local health-care facilities or applying via Taobao and Alipay.


Women planning a pregnancy and mothers-to-be are not recommended to receive vaccinations. Women with cervical cancer and condyloma are banned.


Currently, only two companies, GlaxoSmithKline and Merck, are licensed to make the HPV vaccine.


Last year, GSK got the green light to introduce its vaccine, called Cervarix, to China’s mainland. It started to supply the domestic market this summer.


Cervarix is licensed for use in girls and women aged from 9 to 25. It targets bivalent virus HPV 16 and 18, which are blamed for 70 percent of cervical cancers. Tests show vaccination is almost 100 percent effective for virgins.

Cervarix疫苗在9岁至25岁的女孩和女性中使用。它的免疫目标是二价病毒HPV 16和18,业界认为这两种病毒有70%的概率会诱发宫颈癌。试验表明,接种疫苗对处女来说几乎100%有效。

It requires a series of three injections over a period of six months, which costs a total of 1,756.50 yuan (US$265).


Next year, Merck’s Gardasil, targeting HPV 6, 11, 16 and 18, is set to be introduced to Shanghai as it was licensed in May by the China Food and Drug Administration. It is approved for use in women aged from 20 to 45.

明年,针对HPV 6、11、16和18病毒的默克公司加德西疫苗将引入上海,该疫苗于5月被中国食品和药物管理局授予许可。它被批准用于从20岁到45岁的女性。